- Home
- ORLA vs WGS Comparison
ORLA vs WGS Comparison
Compare ORLA & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORLA
- WGS
- Stock Information
- Founded
- ORLA 2007
- WGS 2017
- Country
- ORLA Canada
- WGS United States
- Employees
- ORLA N/A
- WGS N/A
- Industry
- ORLA Precious Metals
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- ORLA Basic Materials
- WGS Technology
- Exchange
- ORLA Nasdaq
- WGS Nasdaq
- Market Cap
- ORLA 1.3B
- WGS 1.5B
- IPO Year
- ORLA N/A
- WGS N/A
- Fundamental
- Price
- ORLA $3.96
- WGS $68.43
- Analyst Decision
- ORLA Buy
- WGS Strong Buy
- Analyst Count
- ORLA 2
- WGS 5
- Target Price
- ORLA $6.13
- WGS $67.00
- AVG Volume (30 Days)
- ORLA 535.6K
- WGS 753.8K
- Earning Date
- ORLA 11-12-2024
- WGS 10-29-2024
- Dividend Yield
- ORLA N/A
- WGS N/A
- EPS Growth
- ORLA N/A
- WGS N/A
- EPS
- ORLA 0.01
- WGS N/A
- Revenue
- ORLA $314,101,000.00
- WGS $267,228,000.00
- Revenue This Year
- ORLA $35.64
- WGS $43.70
- Revenue Next Year
- ORLA $0.41
- WGS $16.78
- P/E Ratio
- ORLA $284.77
- WGS N/A
- Revenue Growth
- ORLA 38.09
- WGS 29.41
- 52 Week Low
- ORLA $2.60
- WGS $1.29
- 52 Week High
- ORLA $5.17
- WGS $89.11
- Technical
- Relative Strength Index (RSI)
- ORLA 33.77
- WGS 51.05
- Support Level
- ORLA $3.81
- WGS $71.45
- Resistance Level
- ORLA $4.72
- WGS $82.18
- Average True Range (ATR)
- ORLA 0.20
- WGS 7.58
- MACD
- ORLA -0.13
- WGS -1.36
- Stochastic Oscillator
- ORLA 12.16
- WGS 17.21
About ORLA Orla Mining Ltd.
Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Mexico, and the South Railroad and Lewis gold projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.